MedTrace Logo

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

NCT07014540 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-06-11

No results posted yet for this study

Summary

To explore the efficacy and safety of irinotecan liposome injection combined with 5-FU/LV in the treatment of advanced neuroendocrine carcinoma (NEC)

Conditions

  • Neuroendocrine Carcinomas (NEC)

Interventions

DRUG

Irinotecan Hydrochloride Liposome Injection

Liposome irinotecan (70/50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week

DRUG

5-FU

5-FU (2400mg/m\^2) will be administered by continuous infusion for 46 hours in a 2-week

DRUG

LV

LV (400mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week

Sponsors & Collaborators

  • CSPC Ouyi Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Beijing GoBroad Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07014540 on ClinicalTrials.gov